Research Article

BIOMEDICAL Journal of Scientific & Technical Research

ISSN: 2574 -1241

DOI: 10.26717/BJSTR.2022.46.007377

The Production of Each New Drug is a Very Complex Job

Siniša Franjić*

Independent Researcher, Republic of Croatia

***Corresponding author:** Siniša Franjić, Independent Researcher, Republic of Croatia

ARTICLE INFO

Received: September 19, 2022

Published: October 12, 2022

Citation: Siniša Franjić. The Production of Each New Drug is a Very Complex Job. Biomed J Sci & Tech Res 46(4)-2022. BJSTR. MS.ID.007377.

ABSTRACT

Each test is conducted according to a comprehensive plan, called a test plan. It lists the types of patients who can be included in the trial, the schedule of examinations and procedures, medications and their doses, the required follow-up, and the duration of the trial. The investigation plan shall also describe the results to be evaluated and the types of information that are collected and then forwarded to the relevant regulatory authorities in order to obtain authorization to place the investigational medicinal product on the market. Clinical trials are conducted in stages. Each phase is designed to provide answers to specific questions and in each of them appropriate measures are taken to protect participants. Each new therapy is usually tested in three phases of clinical trials before regulators assess it as safe and effective. In addition, trials are conducted in accordance with good clinical practice guidelines required by regulatory authorities to protect patient safety. Clinical trials are research trials conducted in humans to find answers to specific questions about new drugs, vaccines, diagnostic procedures, or new ways of applying known therapies. Clinical trials seek to determine whether new drugs, diagnostic procedures or therapies are safe and effective. Carefully conducted clinical trials are the fastest and safest way to find therapies that help people. After researchers test new drugs or procedures in the laboratory and in animal studies, those who show the best results enter the phase of clinical trials in humans.

Keywords: New Drugs; Drug Development; Drug Use; Clinical Trials

Introduction

In the early days, the important thing to drug discovery frequently become screening programs, in which laboratory-screening models had been used to check new chemical entities for efficacy towards precise disease candidates [1]. Those who had been effective, however, frequently observed a whole lot of their efficiency diminished due to the fact the energetic, usually formulated right into a pill, become attacked through everyday frame chemistry as it exceeded thru the digestive device on its manner to be absorbed into the blood and transported to the disease site. Thus, simplest a fragment of the orally ingested drug reached the drug spot. As a result, dose regimens for plenty oral tablets had been 100–500 mg. These dosing ranges generated needs for big portions of actives in a few instances into the millions of kilograms annually. (Five billion drugs at two hundred mg dose require 1 million kilograms of active.) This led to committed vegetation for each drug energetic, specifically for the reason that energetic become usually a complicated natural molecule requiring many chemical steps to synthesize.

However, with the arrival of the most important goal on biochemistry and additionally the brand-new sophistication won in understanding the chemistry and biology of the frame, contemporary tablets are designed so on be more potent. Additionally, they will be chemically blanketed to restrict the destruction of the drug as it passes thru the frame on its manner to the goal site. Thus, everyday dosing of contemporary ''designer'' tablets are five–20 mg, 10-fold much less than in the past. This reduces the API (active pharmaceutical ingredient) want for ''blockbuster'' tablets through an order of magnitude (five billion drugs at 10 mg dose calls for 50,000 kg of API). This additionally shows that the ones lesser extent merchandise could require very small portions of API making committed centers for them very uneconomical. These elements have refocused API production from centers committed to 1 API product to multiproduct production centers. The brought fees of a facility way to the more rigorous cGMPs that now follow choose those forms of centers, in which the price may be shared through many in place of one product.

Development

There is the merchandising of intentionally overlapping the experimental improvement of the approach with its layout right into a generating plant [2]. Valuable as it is, however, this overlap is normally now no longer used as a sturdy approach in looking for the better system and a generating plant to match, however, is practiced ineffectively, strictly as a need of the time to-marketplace imperative. Sometimes the jurisdictional divide on the improvement=layout boundary is sincerely too deep; or there may be an interdisciplinary gap, with chemists on one aspect and engineers at the different; or the approach layout will become earnest too past due to persuade the improvement. Indeed, many scaleup problems cannot be diagnosed or quantified quickly sufficient without a sufficient system layout attempt that runs parallel and near the improvement. Then, there may be the lessened man or woman that the approach layout subdiscipline has advanced due to the fact the effects of many bulk drug initiatives being dealt with designedly and construction firms, in which the exercise of system layout is unduly conservative, or too pliant to the consumer's wishes, or so missing in the bulk drug processing capabilities so on provide not anything past what the consumer brings to the undertaking, with the consumer's mistakes or barriers dutifully integrated into the layout. In different initiatives, like folks that outsource production, the emphasis on system retrofit into present plant is heavy and additionally the system layout, if any, is normally past the hold close of the consumer. This harsh evaluation is warranted through the consequences frequently paid, unknowingly on the time, because of the lack of the proper system layout capabilities and practices in scaling up bulk drug tactics, or simply through the absence of a mechanism to take benefit of the possibilities in intentionally overlapping system improvement and layout.

Alas, chemical system layout capabilities are not often taught formally; the primary and closing educational exposure maximum engineering students want to the subject can be an instead superficial and exceedingly structured ''system layout'' undertaking on the undergraduate level. to create topics worse, computer software program gear which can resource system layout have usurped that undergraduate task, frequently lowering the student's attempt to little over filling blanks in pretty inflexible templates, a few instances with proposed operational designs that can be hilarious (e.g., a stirred tank for a Kolbe response loaded with 4000 kg of 2-in metallic balls!) and generally lacking the studying enjoy of manipulating layout alternatives on the conceptual level. Yet, sound system layout can be a needful of suitable system overall performance within the works, and creative system layout is nearly necessary in attaining advanced tactics and vegetation, moreover as in exploiting high quality chemistry which can be hard to put into effect in the plant. Thus, the knowledge of fostering the formal improvement of those capabilities and additionally the improvement=layout overlap in commercial exercise; putting emphasis at the conceptual and unstructured aspects, as those are not addressed properly through these computational aids which might be broadly used and are much less probable to be pursued aggressively through engineering layout contractors.

Drug discovery and development are long and arduous processes; recent figures point to 10 years and $2 billion USD to require a brand-new chemical agent from discovery through to market [3]. Moreover, though an approved blockbuster drug can be lucrative for the controlling pharmaceutical company, new therapeutic agents suffer from a 90% attrition during development, making the probabilities of success within the drug development process relatively low. Machine learning (ML) has re-emerged within the last several years as a strong set of tools for unlocking value from large datasets. ML has shown great promise in improving efficiencies across numerous industries with high quality, vast, datasets. In an age of increasing access to highly curated rich sources of biological data, ML shows promise in reversing some of the negative trends shown in drug discovery and development. Even in phase iii trials, drugs can fail thanks to some unforeseen side effect or off target affect. Interestingly, this very property opens up a shortcut for drug development. Over the last several years there has been substantial interest in repurposing existing drugs for new indications. This may be hypothesis driven, where we learn new features of a diseases pathology which make us confident that an existing inhibitor may be useful, or data driven,

where researchers and firms use structure activity relationships to search out serendipitous matches between known disease targets and already approved (or close to approval) drugs.

A truly new drug (one that doesn't simply mimic the structure and action of previously available drugs) requires the invention of a brand-new drug target, ie, the pathophysiologic process or substrate of a disease [4]. Such discoveries are usually made publically sector institutions (universities and research institutes), and molecules that have beneficial effects on such targets are often discovered within the same laboratories. However, the development of new drugs usually takes place in industrial laboratories because optimization of a category of new drugs requires painstaking and expensive chemical, pharmacologic, and toxicologic research. In fact, much of the recent progress within the application of drugs to disease problems may be ascribed to the pharmaceutical industry including "big pharma," the multibillion-dollar corporations that specialize in drug development and marketing. These companies are uniquely skilled in translating basic findings into successful therapeutic breakthroughs and profit-making "blockbusters". Such breakthroughs come at a price; however, and therefore the escalating cost of drugs has become a significant contributor to the inflationary increase within the cost of health care. Development of new drugs is enormously expensive, but considerable controversy surrounds drug pricing. Critics claim that the prices of development and marketing are grossly inflated by marketing activities, advertising, and other promotional efforts, which can consume the maximum amount as 25% or more of a company's budget. Furthermore, profit margins for big pharma are relatively high. Recent drug-pricing scandals are reported during which the right to an older, established drug has been purchased by a smaller company and also the price increased by several hundred or several thousand percent. This "price gouging" has caused public outrage and attracted regulatory attention which will lead to more legitimate and rational pricing mechanisms. Finally, pricing schedules for many drugs vary dramatically from country to country and even within countries, where large organizations can negotiate favorable prices and little ones cannot. Some countries have already addressed these inequities, and it seems likely that each one country will need to do so during the next few decades.

New Medicine

Development of a drug into a medicine is timeconsuming and expensive [5]. It can easily take 10–20 years before a drug becomes an approved medicine. Nowadays, identification of a pharmacological target is usually the first step of drug development. This target should play a key role in a very given disease process. Often, identification of targets is accomplished by knockout models. In these models, mostly mice, a specific gene is inactivated, leading to pathophysiological changes that allow for conclusions about the relevance of a selected target. Following identification of a target, within the next step pharmacologically, active compounds are developed that change the function of the target. Drug development is that the task of a discipline referred to as medicinal chemistry, a crucial field of pharmacy and chemistry. In general, one aims at developing drugs that modulate the target with high selectivity, i.e., with no or minor effects on other targets. Along the thanks to a drug, thousands of substances should be studied. Nowadays, crystal and electron microscopical structures of targets and use of computer-assisted methods (structure- and ligand-based design) constitute integral parts of the drug development process. Drug candidates are extensively analyzed in preclinical studies encompassing studies with recombinant proteins, cell cultures, organ models, and intact animals. Once these studies are successfully completed, the risky and expensive phase of clinical development begins.

In phase 1 of clinical development, drug candidates are examined in healthy volunteers to assess safety, tolerability, and pharmacokinetics. In phase 2, the drug candidate is examined for the first time in patients in terms of pharmacokinetics and efficacy. In these studies, quite often surrogate parameters are determined. Surrogate parameters are assumed to permit predictions on the long-term efficacy of drugs. The most important hurdles within the drug development process are phase 3 studies. In these studies, the efficacy of a drug is examined in large patient cohorts with relevancy valid end points. It's critical that in phase 3 studies, whenever possible, control groups with placebo and a standard therapy are included to see true therapeutic progress. In order to obscure the shortage of therapeutic progress by a new medicine, it's often stated that it's not less effective than the old medicine. After successful completion of the phase 3 studies, the new medicine is approved to enter the drug market. However, even after approval of the new medicine, it's to be critically assessed with regard to efficacy and ADRs, because the therapeutic environment of the clinic and also the doctor's office (realworld situation) often differ quite substantially from the conditions in well-controlled clinical studies. It doesn't happen rarely that a new medicine is being withdrawn from the drug market shortly after approval because efficacy is lower than expected or serious ADRs occur. Therefore, in general, it's a wise policy for the physician to primarily focus on well-established and inexpensive drugs and to possess a critical eye on expensive "innovations."

Biomolecules

The use of complex biomolecules as pharmaceutics has already been correctly exploited, ensuing in blockbuster merchandise [6]. Among those, a few instantaneously examples encompass insulin and adalimumab (advertised as Humira), which on

their very own represent a vast share of this biopharmaceutical market. Nevertheless, biomolecules are especially labile, and their management regularly calls for infusion into the bloodstream. As an outcome of the limited desire of management routes available, modulating their pharmacokinetics is moreover tough to realize. Looking in addition ahead, nucleic acid–primarily based totally tablets are simply next door in the R&D pipeline of the numerous companies, and those are going to be even more traumatic for molecular stabilization and pharmacokinetics modulation. In parallel, the enhancement of difficult small-molecule pharmacokinetics through superior formulations is still a exceptionally applicable purpose for several gamers in the pharmaceutical industry.

The field of modulating molecular functions to get augmented physicochemical profiles for pharmacological software is basically called drug shipping. in the modern-day R&D commercial landscape, drug delivery represents a multidisciplinary improvement of the everyday drug system sector. Since the established order of the Nanotechnology National Institute (NNI) in 2000, nanotechnology has been a warm subject matter in drug delivery, as engineering of nanosized count turned into observed to be especially well-appropriate for interacting with the human frame and controlling drug distribution. However, through specializing in nanometer engineering, the complexity of the drug delivery structures is increased. Hereafter, Quality-through-Trial strategies supported high throughput systematic collection of tries have become incapable of exploring the huge design area growing those complicated merchandise. Therefore, the improvement and production of novel merchandise is shifting closer to excellent-targeted strategies resolving the escalating complexity of the products excellent profile. The passage closer to excellent-primarily based totally rational engineering on medical standards is now guiding pharmaceutical R&D (studies and improvement) and production innovation, representing certainly one of the most appropriate regions for artificial intelligence (AI) implementation.

Drug Use

It is important to notice that, regardless of the level of use, drugs affect different people in several ways [7]. The effects that a psychoactive substance or 'drug experience' will have on a given individual will depend on several other factors beside the pharmacological properties of the drug, like the set and also the setting. The set is that the personality or the psychological state an individual brings to the experience, like thoughts, mood or expectations. The setting refers to the context of the physical or social environment. The pharmacological factors include the chemical properties or sort of drug used. Different drugs have different mode of action on the body because of their pharmacological properties; also important is that the purity and strength of the drug, the route of administration and whether it's used in combination with other drugs. additionally, the effects or actions of a psychoactive drug are influenced by the personal characteristics of the drug user. These characteristics include factors like the person's biological make - up, personality, gender, age and drug tolerance and also the user's previous experience of the drug. The psychological state of the individual is also relevant, for instance those with low mood or who are anxious or depressed are more liable to have disturbing experiences when using psychoactive substances. Health problems like cardiovascular disease, hypertension, asthma, epilepsy, diabetes mellitus or liver disease can exacerbate the use of psychoactive substances and make them more unsafe. The last set of things to be considered is that the setting or context within which a drug is used. This includes the physical environment where the drug is used, the cultural influences of the community where the drug is consumed, the laws referring to drug use and also the context during which a drug is used. it's stated that 'it is necessary to see the drug – brain interaction not as a simple chemical event but as a matter of considerable complexity involving the drug, the particular person, and also the messages and teachings which come from the environment, and which powerfully influence the character and meaning of the drug experience'.

Administration

Drugs will be administered via various routes: oral, sublingual, inhalational, rectal, transdermal, transmucosal, subcutaneous, intramuscular, and intravenous [8]. Oral administration is most typical, and is cheap, easy, and relatively safe. The absorption from the gastrointestinal (GI) tract is determined by surface area, blood flow, and also the concentration and therefore the physical characteristic of the drug. Nonionized (uncharged) types of the drug are more readily absorbed than ionized (charged) forms. Most absorption occurs within the smaller intestine compared to the stomach because of the extremely large area provided by the villi and also the longer transit duration. Accordingly, factors that accelerate gastric emptying will speed the rate of drug absorption while factors that delays gastric emptying will slow the rate of drug absorption. Drugs follow the venous drainage of the stomach and small intestine and are delivered to the liver via the portal system. Therefore, bioavailability of orally administered drugs is restricted to the first pass hepatic metabolism. On the other hand, sublingual and transmucosal drug administration bypass the first pass metabolism because veins of mouth and esophagus drain directly into the inferior vena cava. Around 50% of rectally administered drugs will bypass the liver, potentially increasing the bioavailability compared to orally administered drugs. However, administration of drug rectally may be erratic and incomplete.

additionally, many drugs cause irritation to mucosal membrane. Transdermal absorption depends on the extent, blood flow to the skin, and also the lipid solubility of the drug because the dermis layer is essentially a lipid barrier. Epidermis allows passage of most substances easily. Thus, increased absorption through damaged skin, like from burns, could end in toxicity. Similarly, inflammation increases cutaneous blood flow and also increases transdermal absorption of drugs. samples of transdermal absorption of drugs include fentanyl and scopolamine patches.

Adhesion

Adhesion is a essential characteristic of material behavior inside the pharmaceutical, biomedical, and dental fields that impacts the interactions amongst exclusive materials inside the human frame, and it is also vital as it performs a totally vital function in diverse processes, which includes, however now no longer constrained to, the manufacture of medicine, scientific devices and dental care [9]. Adhesive bonding is a essential location specializing in the advent of joined substrates and composite materials. supported the extensive range of adhesive bonding situations, the idea of adhesion may be widely applied throughout exclusive material kinds and interactions. Mechanisms of adhesion fall into extensive areas: individuals who depend upon mechanical interlocking or entanglement and people that depend upon rate interactions. There are seven time-honored theories of adhesion. These are: mechanical interlocking; electrostatic concept; adsorption (thermodynamic) or wetting concept; diffusion concept; chemical bonding concept; acid-base concept; and concept of susceptible boundary layers. Additionally, elastomeric based adhesives showcase a feature adhesion conduct defined as tackiness or stickiness that aids inside the advent of a nearly instant adhesive bond. The largest undertaking is that the adhesion mechanisms will generally arise in or are inspired through the surroundings of the human frame. The first demanding situations dealing with adhesion inside the surroundings of the human frame consist of: advent of an adhesive bond in contact with diverse physical fluids, blood, saliva, etc.; sturdiness of an adhesive bond while uncovered to various physical fluids; the biochemical onslaught related with the frame's immune reaction and cell regeneration; and publicity to inherent physical microorganisms like microorganism and fungi. Common samples of adhesion inside the pharmaceutical, biomedical, and dental fields consist of the manufacture of respiration inhalants like albuterol; the making use of of scientific bandages like Band-aids used to cowl wounds; and additionally, the usage of denture adhesives to stable fake teeth.

HrQoL

In the evaluation of the extra healing gain of newly authorized drugs, exclusive patient-applicable consequences are used, like Health-related Quality of Life (HrQoL) [10]. Among the 4 consequences (morbidity, mortality, damaging effects), HrQoL is that the maximum subjective and additionally a highly new outcome. This thesis specializes in the relevance of HrQoL records inside the AMNOG process, which includes available devices for the size of HrQoL. Moreover, interviews have been conducted to research exclusive views concerning the relevance of this endpoint as as in comparison to the others. Until now, HrQoL is perceived extra as a supportive tool as opposed to an equal criterion. Possible motives for which can be technical boundaries (reaction rate, confirmed questionnaires) additionally as variations with relevancy the profile of necessities for the pharmaceutical enterprise concerning the marketplace authorization (study design). Since the Act at the Reform of the marketplace for Medicinal Products (AMNOG) got here into effect, the pharmaceutical corporations are dealing with an extra burden with relation to the compensation negotiations with the statutory health insurances. Manufacturers are unfastened to set their fee for a newly authorized drug inside the first yr after marketplace get right of entry to. Since 2011, they must show the extra healing gain of the brand-new drug as a way to negotiate the compensation fee in step with the healing fee. The political purpose become saving the ill budget 2.2 billion € every yr through stemming the unexpectedly growing pharmaceutical expenditures. Moreover, it was delivered to make an honest opposition and to recognition extra at the patients' well-being.

The evaluation of an extra healing gain is primarily based totally on patient-applicable consequences, like mortality, morbidity, and Health-related Quality of Life (HrQoL) in comparison to the first-class of care. the extent of extra gain as in comparison to the precise comparative remedy is classified as: major, significant, marginal, now no longer quantifiable, none or less. the choice of comparator is extraordinarily essential for the drug enterprise, and it is decided through the G-BA (Gemeinsamen Bundesausschuss; Federal Joint Committee), that is that the best selection making frame. The selection is primarily based totally on label and scientific guidelines, the standards for figuring out the proper comparator is written in G-BA's guidelines of procedure.

The brought gain, decided through the G-BA, could be very useful for the drug enterprise with relevance the compensation negotiations with the SHI. If the G-BA reveals that the drug does not have any extra gain, the SHI will pay no pretty what the equal products (often generic drugs) already cost. Thus, the enterprise's purpose is to display some other gain and a higher fee in their newly released drug as in comparison to the proper comparative remedy to recognize a sustainable compensation fee. In general, this wishes a strategic rethinking from the pharmaceutical corporations as

regards to their marketplace get right of entry to strategy. They'll should analyze to stay with an unpredictable marketplace get right of entry to process. Among the 4 consequences, HrQoL is that the maximum subjective and additionally a highly new outcome. The use of patient said consequences (which includes HrQoL) in comparative effectiveness studies will be challenging, as an instance while it entails the selection of appropriate devices or interpretation of results. HrQoL records are tough to get, complicated and subjective. Furthermore, there are technical boundaries with connection with the diverse questionnaires available. The G-BA handiest accepts sure confirmed questionnaires for the evaluation of an extra gain.

RCT

At the time of their marketing, the effects of drugs and especially their efficacy are studied mostly in randomized controlled clinical trials (RCT), comparing them to placebo or to existing drugs [11]. However, these RCT are naturally limited in their extent. Stringent inclusion and exclusion criteria are destined to provide for homogeneous study populations and reduce response variability. These features reduce the representativeness of RCT to the future user population. Once the drugs have proven efficacy and a measure of safety, and are on the market, they're going to be prescribed to patients with concomitant diseases and medicine or other risk factors that have usually been excluded from RCT. When several new drugs are marketed within a brief timeframe, as is often the case with new drug classes (e.g., direct-acting anti-anticoagulants), there's no comparative RCT. It's very unlikely that any pharmaceutical company will devise at great cost a directly comparative RCT, comparing their drug to other direct competitors. additionally, the introduction of new drugs or therapeutic options to the market may shift user populations of previously marketed drugs and modify their benefit–risk balance. There is therefore a requirement to check the interactions drugs with their target populations, within a real-life environment. This includes the description of how it's used (drug utilization studies), how it compares to similar drugs within the identical disease environment (comparative effectiveness), whether any new safety concerns arise, or quantify previously identified concerns (post-authorization safety studies). Additionally, even before a drug is marketed, its future environment and place on the market is anticipated and modelled, as well, once it's effectively been marketed, as its real impact on health economics (health technology assessment).

Costs

One of the great ethical problems of the twenty-first century is that the challenge presented by new drug control and distribution systems [12]. Pharmaceuticals are becoming increasingly expensive. Because the cost of health care rises society will develop ever more sophisticated strategies for containing costs. These will certainly involve efforts to eliminate or control the use of pharmaceuticals that don't seem to be cost-effective. Some drugs currently in use may be eliminated if they will be shown to be ineffective for the patient's condition. That should raise few ethical problems. The controversies will arise when health system planners discover that sometimes a awfully expensive drug is only slightly better than a much cheaper drug. A newly approved agent intended to reduce repeat heart attacks and costing 1000 dollars per patient might, as an example, show a hit rate that's only a tiny bit better than an older agent costing hundreds of dollars. Even claiming that a brand-new drug is "a tiny bit better" is tough to say with certainty, as there are few head-to-head trials. Most clinical trials of new drugs are versus a placebo. A brand name pharmaceutical preferred by a clinician only because she is more confident within the manufacturer costs, on average, four times the generic equivalent that meets all current standards. A continuous-release hypnotic that's chemically identical to the shorter-acting agent that has been on the market for much longer may cost over and over more. Systems managers will realize that the savings obtained by limiting clinicians to the cheaper options can do much more good for patients than permitting indiscriminate use of the more costly alternatives. Pharmacists increasingly find themselves on the committees which will set the standards for formularies used by health system pharmacies and insurers responsible for paying for the price of pharmaceuticals.

Conclusion

An authorization for placing a medicinal product on the market may be granted only for a medicinal product for which it has been determined on the basis of an expert scientific assessment of the medicinal product documentation that it is of appropriate pharmaceutical quality and that the benefit outweighs the risk. Professional scientific assessment is carried out according to pre-defined criteria and norms and standards established in regulations for medicinal products, regulatory and professional guidelines for medicinal products and the latest scientific knowledge. Basic information on approved medicines, including approved summaries of product characteristics and package leaflets, and public evaluation reports on medicinal product dossiers. The public report on the evaluation of the medicinal product dossier is a summary of the detailed reports on the conducted evaluation of the medicinal product dossier, which provides useful and transparent information adapted to the public and does not contain information considered a business secret. After obtaining a marketing authorization for a medicinal product, the marketing authorization holder is obliged to report all changes in the approved medicinal product documentation, information on the medicinal product and the conditions of the granted authorization during the life cycle of the medicinal product.

References

1. Nusim SH (2005) Introduction. In: Nusim SH (Edt.)., Active Pharmaceutical Ingredients Development Manufacturing and Regulation, Taylor & Francis Group Boca Raton USA, p. 5-6.
2. Rosas CB (2005) Bulk Drugs: Process Design, Technology Transfer, and First Manufacture. In: Nusim SH (Edt.)., Active Pharmaceutical Ingredients Development Manufacturing and Regulation, Taylor & Francis Group Boca Raton USA, p. 94-95.
3. Cassidy JW (2020) Applications of Machine Learning in Drug Discovery I: Target Discovery and Small Molecule Drug Design. In: Cassidy JW Taylor B (Edt.)., Artificial Intelligence in Oncology Drug Discovery and Development IntechOpen London UK, p. 17-25.
4. Katzung BM (2018) Introduction: The Nature of Drugs & Drug Development & Regulation. In: Katzung BM (Edt.)., Basic & Clinical Pharmacology (14th Edn.)., McGraw-Hill Education, New York, USA, p. 10-11.
5. Seifert R (2019) Basic Knowledge of Pharmacology, Springer Nature Switzerland AG, Cham, Switzerland, p. 14-15.
6. Colombo S (2020) Applications of artificial intelligence in drug delivery and pharmaceutical development. In: Bohr A Memarzadeh K (Edt.)., Artificial Intelligence in Healthcare, Elsevier, London, UK, p. 86-88.
7. Rassooll GH (2010) Addiction for Nurses, John Wiley & Sons, Chichester, UK, p. 41-42.
8. Hu Y, Maheshwari K (2018) Pharmacology: General Concepts. In: Farag E, Argalious M, Tetzlaff JE, Sharma D (Eds.)., Basic Sciences in Anesthesia, Springer International Publishing AG, Cham, Switzerland, p. 98.
9. Gardner DJ (2017) Theories and Mechanisms of Adhesion in the Pharmaceutical, Biomedical and Dental Fields. In: Mittal KL, Etzler FM (Eds.)., Adhesion in Pharmaceutical, Biomedical, and Dental Fields, Scrivener Publishing LLC, John Wiley & Sons, Inc, Hoboken, USA, p. 4-5.
10. Schneider N (2020) Relevance of Instruments for Measurements of Quality of Life in the AMNOG Context: An Analysis of the Endpoint Health-Related Quality of Life from Different Perspectives. In: Schweizer L, Dingermann T, Russe OQ, Jansen C (Eds.)., Advances in Pharma Business Management and Research, Volume I, Springer Nature Switzerland AG, Cham, Switzerland, p. 7-8.
11. Moore N, Blin P, Droz C (2019) Pharmacoepidemiology. In: Barret JE, Page CP, Michel MC (Eds.)., Concepts and Principles of Pharmacology - 100 Years of the Handbook of Experimental Pharmacology, Springer Nature Switzerland AG, Cham, Switzerland, pp. 434.
12. Veatch RM, Haddad A (2008) Case Studies in Pharmacy Ethics (2nd Edn.)., Oxford University Press, Inc., New York, USA, pp. 215.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2022.46.007377

Siniša Franjić. Biomed J Sci & Tech Res

Submission Link: https://biomedres.us/submit-manuscript.php